Earth Science Tech Inc Revenue Growth Rates (ETST), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Earth Science Tech Inc   (ETST)
 

ETST's Revenue Growth by Quarter and Year

Earth Science Tech Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ETST Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 9.03
FY 9.03

ETSTs Annual Revenue
Earth Science Tech Inc 's Revenue in the fiscal year 2026 $ 35.70 millions
Earth Science Tech Inc 's Revenue in the fiscal year 2025 $ 32.30 millions
Earth Science Tech Inc 's Revenue in the fiscal year 2024 $ 11.95 millions
Earth Science Tech Inc 's Revenue in the fiscal year 2023 $ 0.05 millions
Earth Science Tech Inc 's Revenue in the fiscal year 2022 $ 0.01 millions




ETST Revenue first quarter 2026 Y/Y Growth Comment
Earth Science Tech Inc reported Revenue increase of 11.57% year on year in the first quarter 2026, to $ 9.03 millions, this is lower than Earth Science Tech Inc 's recent average Revenue rise of 66.08%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 126 other companies have achieved higher Revenue growth. While Earth Science Tech Inc ' s Revenue growth of 11.57% ranks overall at the positon no. 2608 in the first quarter 2026.


ETST Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter March - 9.45 % 44.19 % 11940 %
3rd Quarter December - 0.68 % 117.46 % -
2nd Quarter September - 2.35 % 341.45 % -
1st Quarter June 11.57 % -5.6 % 3795.45 % -
FY   - 1.78 % 186.75 % -

Financial Statements
Earth Science Tech Inc 's first quarter 2026 Revenue $ 9.03 millions ETST's Income Statement
Earth Science Tech Inc 's first quarter 2025 Revenue $ 8.09 millions Quarterly ETST's Income Statement


ETST Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter March - 28.38 % 18.1 % 78.11 %
3rd Quarter December - -15.14 % -13.73 % 75.13 %
2nd Quarter September - 7.79 % -0.58 % 777.27 %
1st Quarter June -4.99 % -6.8 % 42.36 % 340 %
FY (Year on Year)   - 1.78 % 186.75 % -


Back to ETST Growth rate Comparisons >> Back to ETST Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #127
Healthcare Sector #374
Overall #2608

Revenue Y/Y Growth Statistics
High Average Low
1105.75 % 66.08 % -89.98 %
(Sep 30 2024)   (Mar 31 2022)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #127
Healthcare Sector #374
Overall #2608
Revenue Y/Y Growth Statistics
High Average Low
1105.75 % 66.08 % -89.98 %
(Sep 30 2024)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Earth Science Tech Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1716.19 % 70.63 % -100 %
(Mar 31 2023)  


ETST's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Earth Science Tech Inc disclosed fall in Revenue from the fourth quarter by -4.99% to $ 9.03 millions, from $ 9.50 millions achived in the previous reporting period.

But that's not important problem, as Earth Science Tech Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Earth Science Tech Inc 's Revenue growth quarter on quarter, overall rank is 3224.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #449
Overall #3224
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #449
Overall #3224
Revenue Q/Q Growth Statistics
High Average Low
1716.19 % 70.63 % -100 %
(Mar 31 2023)  


ETST's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Earth Science Tech Inc disclosed fall in Revenue from the fourth quarter by -4.99% to $ 9.03 millions, from $ 9.50 millions achived in the previous reporting period.

But that's not important problem, as Earth Science Tech Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Earth Science Tech Inc 's Revenue growth quarter on quarter, overall rank is 3224.


Earth Science Tech Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 34.65 $ 33.71 $ 32.89 $ 32.84 $ 32.64
Y / Y Revenue Growth (TTM) 6.15 % 1.79 % 7.99 % 24.03 % 64.11 %
Year on Year Revenue Growth Overall Ranking # 238 # 1 # 0 # 16 # 12
Seqeuential Revenue Change (TTM) 2.77 % 2.5 % 0.14 % 0.63 % -1.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 2644 # 55 # 0 # 142 # 89


Cumulative Revenue growth Comment
Although Earth Science Tech Inc 's Annual Revenue growth year on year were below company's average 66.08% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.15% year on year, from 1.79% in Mar 31 2026.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 238.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 59
Overall # 238

Revenue TTM Y/Y Growth Statistics
High Average Low
1105.75 %
 66.08 %
-89.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 130
Sector # 377
S&P 500 # 2644
Cumulative Revenue growth Comment
Although Earth Science Tech Inc 's Annual Revenue growth year on year were below company's average 66.08% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.15% year on year, from 1.79% in Mar 31 2026.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 238.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 59
Overall # 238

Revenue TTM Y/Y Growth Statistics
High Average Low
1105.75 %
66.08 %
-89.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 130
Sector # 377
S&P 500 # 2644




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ETST's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Castle Biosciences Inc 20.14%$ 20.140 millions
Procept Biorobotics Corporation20.00%$ 20.004 millions
Biomarin Pharmaceutical Inc19.91%$ 19.905 millions
Cannapharmarx Inc 19.26%$ 19.261 millions
Anika Therapeutics Inc 19.18%$ 19.176 millions
Bioaffinity Technologies Inc 18.99%$ 18.992 millions
Aurinia Pharmaceuticals Inc 18.87%$ 18.872 millions
Camp4 Therapeutics Corporation18.84%$ 18.838 millions
Lensar Inc 18.37%$ 18.371 millions
Immunocore Holdings Plc18.34%$ 18.336 millions
Innovage Holding Corp 18.31%$ 18.307 millions
Koru Medical Systems Inc 18.15%$ 18.153 millions
Clearpoint Neuro Inc 18.07%$ 18.068 millions
Avita Medical Inc 17.83%$ 17.830 millions
Xencor Inc17.46%$ 17.458 millions
Logicmark Inc17.39%$ 17.387 millions
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions


About Earth Science Tech Inc Revenue Growth Rates (ETST), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Earth Science Tech Inc (CIK 1538495).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-036450
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Earth Science Tech Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.